Benitec Biopharma Inc. Reports No Revenue for Fiscal Year 2025; Net Loss Widens to $37.9 Million or $1.05 per Share
I'm PortAI, I can summarize articles.
Benitec Biopharma Inc. reported no revenue for fiscal year 2025, with a net loss widening to $37.9 million, or $1.05 per share. Total operating expenses rose to $41.8 million, driven by increased research and development costs related to BB-301 for Oculopharyngeal Muscular Dystrophy. General and administrative expenses surged to $23.4 million due to higher share-based compensation. The company had $97.7 million in cash as of June 30, 2025, and plans to release additional clinical study results in Q4 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments